620116-53-2

Upstream product

• 620116-51-0 (5S,6S)-5-(Dimethyl-phenyl-silanyl)-6-((S)-4-isopropyl-4,5-dihydro-oxazol-2-yl)-5,6-dihydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid allyl ester 
• 3839-31-4 dimethyl(phenyl)silyllithium 

Downstream Products

• 620116-56-5 (5S,5aS,8aR,9R)-5-(Dimethyl-phenyl-silanyl)-8-oxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester 
• 620116-55-4 (5S,6S)-5-(Dimethyl-phenyl-silanyl)-6-(3,4,5-trimethoxy-phenoxythiocarbonyloxymethyl)-5,6-dihydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid allyl ester 
• 620116-57-6 (5aR,8aR,9R)-5,8-Dioxo-9-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5a-carboxylic acid allyl ester 
• 55515-07-6 (1α,2α,3α)-podophyllotoxin 
• 620116-54-3 (5S,6S)-5-(Dimethyl-phenyl-silanyl)-6-hydroxymethyl-5,6-dihydro-naphtho[2,3-d][1,3]dioxole-6-carboxylic acid allyl ester 

Relevant academic research and scientific papers

The intramolecular carboxyarylation approach to podophyllotoxin

Since 1960, only seven plant-derived anticancer drugs have received FDA approval for commercial production. Two are semisynthetic derivatives of podophyllotoxin. This paper describes concise, highly convergent, and conceptually novel approaches to (-)-pod